



(51) International Patent Classification:

C12Q 1/68 (2006.01) *A61K 39/395* (2006.01)
G01N 33/50 (2006.01) *A61P 35/00* (2006.01)
G06F 19/18 (2011.01) *C12N 15/115* (2010.01)
A61K 31/7088 (2006.01) *C07K 16/18* (2006.01)

(21) International Application Number:

PCT/SG2015/050253

(22) International Filing Date:

11 August 2015 (11.08.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201404800X 11 August 2014 (11.08.2014) SG

(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY
AND RESEARCH (A*STAR) [SG/SG]; 1 Fusionopolis
Way, #20-10 Connexis, Singapore 138632 (SG).(72) Inventors: BATAGOV, Arsen Olegovich; c/o Bioinform-
atics Institute, 30 Biopolis St, Matrix, #07-01, Singapore
138671 (SG). IVSHINA, Anna Vladimirovna; c/o Bioin-

formatics Institute, 30 Biopolis St, Matrix, #07-01, Singa-
pore 138671 (SG). YENAMANDRA, Surya Pavan; c/o
Bioinformatics Institute, 30 Biopolis St, Matrix, #07-01,
Singapore 138671 (SG). KUZNETSOV, Vladimir An-
dreevich; c/o Bioinformatics Institute, 30 Biopolis St, Mat-
rix, #07-01, Singapore 138671 (SG).

(74) Agent: POH, Chee Kian, Daniel; Marks & Clerk Singa-
pore LLP, Tanjong Pagar, P O Box 636, Singapore 910816
(SG).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: A METHOD FOR PROGNOSIS OF OVARIAN CANCER, PATIENT'S STRATIFICATION




Figure 4

(57) Abstract: There are no reliable clinical bio-markers of survival prognosis, patient's risk stratification and treatment prediction for epithelial ovarian cancers (EOC). The most common type of the human EOC is a high grade serous EOC. This cancer is characterized with one of the lowest survival rates compared to other cancers. The present invention relates to an method for a prognosis of survival of a subject diagnosed with EOC, the method comprising determining in a sample of the subject gene expression level of at least one gene in the list of *Evi1* pathway genes; and/or copy number of at least one gene in the *MECOM* locus; wherein the level against at least one expression threshold value will define the risk group of the subject and/or a risk of the disease progression after surgery treatment, and/or an effectiveness of post-surgery chemotherapy. The quantification method of *Evi1/MECOM* locus regulatory pathway provides a set of multigene prognostic signatures representing *EVI1* pathway modules, which collectively provided a framework of high-confidence, sensitive and specific prognosis assay(s) of EOC and stratification method for the EOC patient stratification according to disease relapse.



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*